Skip to content
Home » Menicon Co., Ltd. Announcement of medical device approval for “Sears”, a material that secures visual fiel d during glaucoma surgery

Menicon Co., Ltd. Announcement of medical device approval for “Sears”, a material that secures visual fiel d during glaucoma surgery

[Menicon Co., Ltd.] Announcement of medical device approval for “Sears”, a material that secures visual field during glaucoma surgery
*View in browser* *Menicon Co., Ltd.*
Press release: July 2, 2024
**
Announcement of medical device approval for Sears, a material that secures visual field during glaucoma surgery

* Information for the press *
This website provides information on the Menicon Group companies and related information for members of the domestic press. Please note that this is not intended to provide information to the general public.
July 2, 2024
National University Corporation Osaka University
National University Corporation Okayama University
Menicon Co., Ltd.

National University Corporation Osaka University (Headquarters: Suita City, Osaka Prefecture, President: Shojiro Nishio) Graduate School of Medicine (hereinafter referred to as “Osaka University”), National University Corporation Okayama University (Headquarters: Okayama City, Okayama Prefecture, President: Yasutomo Nasu) , hereinafter “Okayama University”), Menicon Co., Ltd. (Head office: Nagoya City, Aichi Prefecture, Representative Executive Officer and President)
We would like to inform you that “Sears”, an ophthalmic field-of-view material jointly developed by COO: Yasushi Kawaura), has been approved as a new medical device in Japan as of June 3, 2024.
The newly approved medical device, which uses self-assembling peptide gel technology, is expected to improve visibility of the surgical field during glaucoma surgery and contribute to the provision of better medical care.

-Background of medical device development-

Treatment for glaucoma*1 includes drug therapy, laser therapy, and surgery, and surgery is generally performed when drug therapy and laser therapy are unsuccessful. With the diversification of glaucoma drug therapy in recent years, patients undergoing surgery often experience conjunctival hyperemia as a side effect of long-term drug therapy. As a result, a large amount of bleeding occurs during surgery, and blood accumulates at the surgical site, making its visibility very poor.
For this reason, surgery is currently performed while ensuring visibility by continuing extremely complicated procedures such as wiping the blood, suctioning it, and washing it away with
physiological saline. Performing surgery under such poor visibility not only puts stress on the doctor, but also increases the burden on the patient by prolonging the surgery time and reducing surgical safety.

-Development details-

The Department of Systems Physiology, Graduate School of Biomedical Sciences, Okayama University and Menicon Co., Ltd. have developed a self-assembling peptide (SPG-178*2). SPG-178 forms a hydrogel with a three-dimensional network when dissolved in water. This hydrogel is highly stable and transparent at neutral pH, and has high
biocompatibility, so it was expected to be applied in the medical field.

Osaka University Graduate School of Medicine Department of
Neurosensory Surgery (Ophthalmology) and Menicon Co., Ltd. have developed a self-assembling peptide (SPG-178) gel that maintains its internal transparency even when there is blood around it. We investigated the optimal composition as a material to ensure visibility during glaucoma surgery using glaucoma, and conducted numerous non-clinical and human clinical trials. We also demonstrated its usefulness as a medical device during glaucoma surgery.

The ophthalmological visual field securing material “Sears”, which is a result of this research and development, improves the visibility of the surgical site due to a large amount of intraoperative bleeding during glaucoma surgery, which is necessary for glaucoma treatment, and improves the visibility of the surgical site. It is expected to not only reduce stress but also reduce the burden on patients by improving surgical safety.

*1 Glaucoma

This is a disease in which the optic nerve, which transmits
information from the eyes to the brain, is damaged, resulting in a narrowing of the field of vision. The main cause is said to be increased intraocular pressure, and the incidence rate in Japan is extremely high, at 5% in people over 40 years old and over 10% in people over 60 years old, and accounts for about 40% of acquired blindness in Japan. It is the number one cause of acquired blindness.

*2 SPG-178

It is a peptide made by linking 13 of 4 types of amino acids (arginine, leucine, aspartic acid, and alanine). This peptide naturally and regularly aggregates in water to form nanometer-sized fibers. By intertwining three-dimensionally and creating a mesh structure, a transparent gel containing a large amount of water is formed.

-Approval summary-
○ Medical device approval number 30600BZX00110000
○ Name
・General name: Ophthalmic visual field securing material
・Sales name: Sears
○ Class classification III
○ Purpose of use or effect
Surgical assistance during open glaucoma surgery (ensuring visibility) This product is a field-of-view material used during open glaucoma surgery to prevent blood from flowing into the surgical site and facilitate observation.

-Research representative at the university-
Osaka University Graduate School of Medicine Department of
Neurosensory Surgery (Ophthalmology) Koji Nishida, Kenji Matsushita Keiji Naruse, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University

-Contact information-
・Osaka University
Kenji Matsushita
Osaka University Graduate School of Medicine, Neurosensory Surgery (Ophthalmology), Associate Professor
 TEL: 06-6879-3456
 E-mail: kenmatsu@ophthal.med.osaka-u.ac.jp

Osaka University Graduate School of Medicine Public Relations Office  TEL: 06-6879-3387
 E-mail: medpr@office.med.osaka-u.ac.jp

・Okayama University
Okayama University General Affairs and Planning Department Public Relations Division
 TEL: 086-251-7292
 E-mail: kouhou@adm.okayama-u.ac.jp

・Menicon Co., Ltd.
External Relations and Public Relations Department
 TEL: 052-935-1187
 E-mail: presscontact@menicon.co.jp
*About details about this release*
https://prtimes.jp/main/html/rd/p/000000336.000005623.html

*Download press release materials*
https://prtimes.jp/im/action.php?run=html&page=releaseimage&company_id=5623&release_id=336


Unsubscribe HTML email

Copyright © PR TIMES Corporation All Rights Reserved.